Peptides and methods for the treatment of diabetes
The invention relates to peptides such as HCPYCSLQPLALEGSLQKRG and their use in the treatment of type 1 diabetes and the generation of cytolytic CD4+ T cell.
1. An isolated immunogenic peptide with a length of between 12 and 50 amino acids, comprising the amino acid sequence HCxx[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]xxCSLQPLALEGSLQK [ SEQ ID NO:8].
2. The peptide according to claim 1 , comprising the amino acid sequence HCxxCSLQPLALEGSLQK [SEQ ID NO: 9].
3. The peptide according to claim 1 , consisting of the amino acid sequence HCPYCSLQPLALEGSLQKRG [SEQ ID NO: 26].
4. A pharmaceutical composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier.
5. A pharmaceutical composition comprising the peptide of claim 2 and a pharmaceutically acceptable carrier.
6. A pharmaceutical composition comprising the peptide of claim 3 and a pharmaceutically acceptable carrier.
7. The peptide according to claim 1 , consisting of the amino acid sequence HCxx[CST]SLQPLALEGSLQK [SEQ ID NO:7] or H[CST]xxCSLQPLALEGSLQK [SEQ ID NO:8].
8. The peptide according to claim 1 , consisting of the amino acid sequence HCxxCSLQPLALEGSLQK [SEQ ID NO: 9].
9. A pharmaceutical composition comprising the peptide of claim 7 and a pharmaceutically acceptable carrier.
10. A pharmaceutical composition comprising the peptide of claim 8 and a pharmaceutically acceptable carrier.